Hyperuricemia, gout and high cardiovascular risk - how to manage them in clinical practice


Cite item

Full Text

Abstract

In recent years, the relationship of hyperuricemia and gout with a high risk of cardiovascular disease has been widely discussed. Therefore, it is important to systematically examine patients in order to diagnose comorbidities, among which cardiovascular disease and its complications occupy a leading place and consider mandatory treatment of patients with hyperuricemia and gout with high cardiovascular risk with lowering drugs, which fully reflects the provisions of the latest European recommendations for the management and treatment of patients with gout.

About the authors

V V Fomin

Sechenov First Moscow State Medical University (Sechenov University)

Moscow, Russia

T E Morosova

Sechenov First Moscow State Medical University (Sechenov University)

Moscow, Russia

V V Tsurko

Sechenov First Moscow State Medical University (Sechenov University); Pirogov Russian National Research Medical University

Moscow, Russia

References

  1. Richette P, Doherty M, Pascual E, еt al. EULAR evidence - based recommendations for the management of gout. Ann Rheum Dis. 2016. doi: 10.1136/annrheumdis-2016-209707
  2. Zhu Y, Pandya B.J, Choi H.K. Prevalence of gout and hyperuricemia in the US general population: the National Health and Nutrition Examination Survey 2007-2008. Arthritis Rheum. 2011;63(10):3136-41. doi: 10.1002/art.30520
  3. Lin К.С, Lin H.Y, Chou R. The interaction between uric acid level and other risk factors on the development of gout among asymptomatic hyperuricemic men in a prospective study. J Rheumatol. 2000;27(6):1501-5.
  4. Simkin P.A. The pathogenesis of podagra. Ann Intern Med. 1977;86:230-3.
  5. Компания «ЭГИС» собрала статистику о распространенности гиперурикемии в сочетании с артериальной гипертензией и сопутствующими заболеваниями среди российских пациентов. Поликлиника. Спецвыпуск. 2017;(4):16.
  6. Mazzali M, Hughes J, Kim Y.G, Jefferson J.A, Kang D.H, Gordon K.L, Lan H.Y, Kivlighn S, Johnson R.J. Elevated uric acid increases blood pressure in the rat by a novel crystal - independent mechanism. Hypertension. 2001;38(5):1101-6.
  7. Perez-Pozo S.E, Schold J, Nakagawa T, Sanchez-Lozada L.G, Johnson R.J, Lillo J.L. Excessive fructose intake induces the features of metabolic syndrome in healthy adult men: role of uric acid in the hypertensive response. Int J Obes (Lond). 2010;34(3):454-61.
  8. De Bosch B.J, Kluth O, Fujiwara H, Schurmann A, Moley K. Early - onset metabolic syndrome in mice lacking the intestinal uric acid transporter SLC2A9. Nat Commun. 2014;5:4642. doi: 10.1038.ncomms5642
  9. Feig D.I, Kang D.H, Johnson R.J. Uric acid and cardiovascular risk. N Engl J Med. 2008;359(17):1811-21. doi: 10.1056 / NEJMra0800885
  10. Richette P, Perez-Ruiz F, Doherty M, Jansen T.L, Nuki G, Pascual E, Punzi L, So A.K, Bardin T. Improving cardiovascular and renal out - comes in gout: what should we target? Nat Rev Rheumatol. 2014;10(11):654-61. doi: 10.1016/j.jare.2017.04.008
  11. Andres M, Quintanilla M.A, Sivera F, Sanchez-Paya J, Pascual E, Vela P, Ruiz-Nodar J.M. Silent monosodium urate crystal deposits are associated with severe coronary calcification in asymptomatic hyperuricemia: an exploratory study. Arthritis Rheum. 2016;68(6):1531-9. doi: 10.1002/art.39581
  12. Saito Y, Nakayama T, Sugimoto K, Fujimoto Y, Kobayashi Y. Relation of lipid content of coronary plaque to level of serum uric acid. Am J Cardiol. 2015;116(9):1346-50. doi: 10.1016/j.amjcard.2015.07.059
  13. Ando K, Takahashi H, Watanabe T, Daidoji H, Otaki Y, Nishiyama S, Arimoto T, Shishido T, Miyashita T, Miyamoto T, et al. Impact of serum uric acid levels on coronary plaque stability evaluated using integrated backscatter intravascular ultrasound in patients with coronary artery disease. J Atheroscler Thromb. 2016;23(8):932-9. doi: 10.5551/jat.33951
  14. Park J.J, Roudier M.P, Soman D, Mokadam N.A, Simkin P.A. Prevalence of birefringent crystals in cardiac and prostatic tissues, an observational study. BMJ Open. 2014;4(7):e005308. doi: 10.1136/bmjopen-2014-005308
  15. Borghi C, Rosei E.A, Bardin T, Dawson J, Dominiczak A, Kielstein J.T, Manolis A.J, Perez-Ruiz F, Mancia G. Serum uric acid and the risk of cardiovascular and renal disease. J Hypertens. 2015;33(9):1729-41. doi: 10.1097/HJH.0000000000000701
  16. Zhao G, Huang L, Song M, Song Y. Baseline serum uric acid level as a predictor of cardiovascular disease related mortality and al. l - cause mortality: a meta - analysis of prospective studies. Atherosclerosis. 2013;231(1):61-8. doi: 10.1016/j.atherosclerosis.2013.08.023
  17. Nozue T, Yamamoto S, Tohyama S, Fukui K, Umezawa S, Onishi Y, Kunishima T, Hibi K, Terashima M, Michishita I. Correlations between serum uric acid and coronary atherosclerosis before and during statin therapy. Coron Artery Dis. 2014;25(4):343-8. doi: 10.1097/MCA.0000000000000084
  18. Tamariz L, Hernandez F, Bush A, Palacio A, Hare J.M. Association between serum uric acid and atrial fibrillation: a systematic review and meta - analysis. Heart Rhythm. 2014;11(7):1102-8. doi: 10.1016/j/hrthm.2014.04.003
  19. Kim S.Y, Guevara J.P, Kim K.M, Choi H.K, Heitjan D.F, Albert D.A. Hyperuricemia and risk of stroke: a systematic review and meta - analysis. Arthritis Rheum. 2009;61(7):885-92. doi: 10.1002 / art. 24612
  20. Harzand A, Tamariz L, Hare J.M. Uric acid, heart failure survival, and the impact of xanthine oxidase inhibition. Congest Heart Fail. 2012;18(3):179-82. doi: 10.1111/j.1751-7133.2011.00262.x.
  21. Bardin T, Richette Р. Impact of comorbidities on gout and hyperuricemia: an updated on prevalence and treatment options. BMC Med. 2017;15:123. doi: 10.1186/s12916-017-0890-9
  22. Lyngdoh T, Vuistiner P, Marques-Vidal P, Rousson V, Waeber G, Vollenweider P, Bochud M. Serum uric acid and adiposity: deciphering causality using a bidirectional Mendelian randomization approach. PLoS One. 2012;7(6):e39321. doi: 10.1371/journal.pone.0039321
  23. Nitsch D, Molokhia M, Smeeth L, De Stavola B.L, Whittaker J.C, Leon D.A. Limits to causal inference based on Mendelian randomization: a comparison with randomized controlled trials. Am J Epidemiol. 2006;163(5):397-403. doi: 10.1093/aje/kwj062
  24. Doring A, Gieger C, Mehta D, Gohlke H, Prokisch H, Coassin S, Fischer G, Henke K, Klopp N, Kronenberg F, et al. SLC2A9 influences uric acid concentrations with pronounced sex - specific effects. Nat Genet. 2008;40(4):430-6. doi: 10.1038/ng.107
  25. Parsa A, Brown E, Weir M.R, Fink J.C, et al. Genotype - based changes in serum uric acid affect blood pressure. Kidney Int. 2012;81(5):502-7. doi: 10.1038/ki.2011.414
  26. Mallamaci F, Testa A, Leonardis D, Tripepi R, Pisano A, Spoto B, Sanguedolce M.C, Parlongo R.M, Tripepi G, Zoccali C. A polymorphism in the major gene regulating serum uric acid associates with clinic SBP and the white - coat effect in a family - based study. J Hypertens. 2014;32(8):1621-8. doi: 10.1097/HJH.0000000000000224
  27. Mallamaci F, Testa A, Leonardis D, Tripepi R, Pisano A, Spoto B, Sanguedolce M.C, Parlongo R.M, Tripepi G, Zoccali C. A genetic marker of uric acid level, carotid atherosclerosis, and arterial stiffness: a family - based study. Am J Kidney Dis. 2015;65(2):294-302. doi: 10.1038/ki.2011.414
  28. Palmer T.M, Nordestgaard B.G, Benn M, Tybjaerg-Hansen A, Davey Smith G, Lawlor D.A, Timpson N.J. Association of plasma uric acid with ischaemic heart disease and blood pressure: Mendelian randomisation analysis of two large cohorts. BMJ. 2013;347:f4262. doi: 10.1136/bmj.f4262
  29. Mc Keigue P.M, Campbell H, Wild S, Vitart V, Hayward C, Rudan I, Wright A.F, Wilson J.F. Bayesian methods for instrumental variable analysis with genetic instruments (‘Mendelian randomization’): example with urate transporter SLC2A9 as an instrumental variable for effect of urate levels on metabolic syndrome. Int J Epidemiol. 2010;39(3):907-18. doi: 10.1093/ije/dyp397
  30. Kleber M.E, Delgado G, Grammer T.B, Silbernagel G, Huang J, Kramer B.K, Ritz E, Marz W. Uric acid and cardiovascular events: a Mendelian randomization study. J Am Soc Nephrol. 2015;26(11):2831-8. doi: 10.1681/ASN.2014070660
  31. Yan D, Wang J, Jiang F, et al. A causal relationship between uric acid and diabetic macrovascular disease in Chinese type 2 diabetes patients: a Mendelian randomization analysis. Int J Cardiol. 2016;214:194-9. doi: 10.1016 / j. ijcard.2016.03.206
  32. Yang Q, Kottgen A, Dehghan A, Smith A.V, Glazer N.L, Chen M.H, Chasman D.I, Aspelund T, Eiriksdottir G, Harris T.B, et al. Multiple genetic loci influence serum urate levels and their relationship with gout and cardiovascular disease risk factors. Circ Cardiovasc Genet. 2010;3(6):523-30. doi: 10.1161/CIRCGENETICS.109.934455
  33. Keenan T, Zhao W, Rasheed A, Ho W.K, Malik R, Felix J.F, Young R, Shah N, Samuel M, Sheikh N, et al. Causal assessment of serum urate levels in cardiometabolic diseases through a Mendelian randomization study. J Am Coll Cardiol. 2016;67(4):407-16. doi: 10.1016/j.jacc.2015.10.086
  34. Sedaghat S, Pazoki R, Uitterlinden A.G, Hofman A, Stricker B.H, Ikram M.A, Franco O.H, Dehghan A. Association of uric acid genetic risk score with blood pressure: the Rotterdam study. Hypertension. 2014;64(5):1061-6. doi: 10.1161/HYPERTENSIONAHA.114.03757Hypertension
  35. Higgins P, Dawson J, Lees K.R, Mc Arthur K, Quinn T.J, Walters M.R. Xanthine oxidase inhibition for the treatment of cardiovascular disease: a systematic review and meta - analysis. Cardiovasc Ther. 2012;30(4):217-26. doi: 10.1111/j.1755-5922.2011.00277.x
  36. Scheepers L.E, Wei F.F, Stolarz-Skrzypek K, Malyutina S, Tikhonoff V, Thijs L, Salvi E, Barlassina C, Filipovsky J, Casiglia E, et al. Xanthine oxidase gene variants and their association with blood pressure and incident hypertension: a population study. J Hypertens. 2016;34(11):2147-54. doi: 10.1097/HJH0000000000001077
  37. Scheepers L.E, Boonen A, Pijnenburg W, Bierau J, Staessen J.A, Stehouwer C.D, Thijs C, Arts I.C. Associations of plasma uric acid and purine metabolites with blood pressure in children: the KOALA Birth Cohort Study. J Hypertens. 2017;35(5):982-93. doi: 10.1097/HJH.0000000000001270
  38. Schmitz B, Brand S.M. Uric acid and essential hypertension: the endothelial connection. J Hypertens. 2016;34(11):2138-9. doi: 10.1097/HJH.0000000000001109
  39. Hootman J.M, Helmick C.G. Projections of US prevalence of arthritis and associated activity limitations. Arthritis Rheum. 2006;54:226-9. doi: 10.1002/art. 21562
  40. Kuo C.F, Luo S.F. Gout: risk of premature death in gout unchanged for years. Nat Rev Rheumatol. 2017;13(4):200-1. doi: 10.1038/nrrheum.2017.27
  41. Culleton B.F, Larson M.G, Kannel W.B, Levy D. Serum uric acid and risk for cardiovascular disease and death: the Framingham Heart Study. Ann Intern Med. 1999;131(1):7-13. doi: 10.7326/0003-4819-131-1-199907060-00003
  42. So A, Thorens B. Uric acid transport and disease. J Clin Invest. 2010;120:1791-9. doi: 10.1172/JCI42344
  43. Rock K.L, Kataoka H, Lai J.J. Uric acid as a danger signal in gout and its comorbidities. Nat Rev Rheumatol. 2013;9:13-23. doi: 10.1038/nrrheum.2012.143
  44. Kumar H.K.V.S, Marwaha V. Chronic Tophaceous Gout. Int J Med Health Sci. 2012;1(1):31-2.
  45. Liu S.C, Xia L, Zhang J, et al. Gout and risk of myocardial infarction: a systematic review and meta - analysis of cohort studies. PLoS ONE. 2015;10:e0134088.
  46. Clarson L.E, Hider S.L, Belcher J, et al. Increased risk of vascular disease associated with gout: a retrospective, matched cohort study in the UK clinical practice research datalink. Ann Rheum Dis. 2015;74:642-7. doi: 10.1136/annrheumdis-2014-205252
  47. Choi H.K, Curhan G. Independent impact of gout on mortality and risk for coronary heart disease. Circulation. 2007;116:894-900. doi: 10.1161/CIRCULATIONAHA.107.703389
  48. Егоров И.В., Хитрик Н.М., Цурко В.В. Функциональное состояние нейтрофилов у пожилых больных хроническим подагрическим артритом в стадии обострения. Клиническая геронтология. 2008;(9):70-1.
  49. Perez-Ruiz F, Martinez-Indart L, Carmona L, Herrero-Beites A.M, Pijoan J.I, Krishnan E. Tophaceous gout and high level of hyperuricaemia are both associated with increased risk of mortality in patients with gout. Ann Rheum Dis. 2014;73(1):177-82. doi: 10.1136/annrheumdis-2012-202421
  50. Edwards N.L. The role of hyperuricemia and gout in kidney and cardiovascular disease. Clev Clin J Med. 2008;75:13-6. doi: 10.3949/ccjm.75.suppl5.s13
  51. Johnson R.J, Kang D.H, Feig D, et al. Is there a pathogenetic role for uric acid in hypertension and cardiovascular and renal disease? Hypertension. 2003;41:1183-90. doi: 10.1161/01.HYP.0000069700.62727.C5
  52. Briggs A.M, Cross M.J, Hoy D.G, et al. Musculoskeletal Health Conditions Represent a Global Threat to Healthy Aging: A Report for the 2015 World Health Organization World Report on Ageing and Health. Gerontologist. 2016;56(Suppl 2):S243-255. doi: 10.1093/geront/gnw002
  53. Clauw D.J. Diagnosing and treating chronic musculoskeletal pain based on the underlying mechanism(s). Best Pract Res Clin Rheumatol. 2015;29(1):6-19. doi: 10.1016/j.berh.2015.04.024
  54. Цурко В.В., Егоров И.В., Елисеева М.В. Подагра у пожилых пациентов, связь с коморбидностью. Практикующий врач сегодня. 2013;(1):2-8.
  55. Kuo C.F, Grainge M.J, Mallen C, Zhang W, Doherty M. Comorbidities in patients with gout prior to and following diagnosis: case - control study. Ann Rheum Dis. 2016;75(1):210-7. doi: 10.1136/annrheumdis-2014-206410
  56. Choi H.K, Ford E.S, Li C, Curhan G. Prevalence of the metabolic syndrome in patients with gout: the Third National Health and Nutrition Ex - amination Survey. Arthritis Rheum. 2007;57(1):109-15. doi: 10.1002/art.22466
  57. Clarson L.E, Hider S.L, Belcher J, et al. Increased risk of vascular disease associated with gout: a retrospective, matched cohort study in the UK clinical practice research datalink. Ann Rheum Dis. 2015;74:642-7. doi: 10.1136/annrheumdis-2014-205252
  58. Елисеев М.С., Новикова А.М. Коморбидность при подагре и гиперурикемии: распространенность, причины, перспективы уратснижающей терапии. Терапевтический архив. 2019;91(5):120-8. doi: 10.26442/00403660.2019. 05.000232
  59. Krishnan E, Baker J.F, Furst D.E, Schumacher H.R. Gout and the risk of acute myocardial infarction. Arthritis Rheum. 2006;54(8):2688-96. doi: 10.1002/art.22014
  60. De Vera M.A, Rahman M.M, Bhole V, Kopec J.A, Choi H.K. Independent impact of gout on the risk of acute myocardial infarction among elderly women: a population - based study. Ann Rheum Dis. 2010;69(6):1162-4. doi: 10.1136/ard.2009.122770
  61. Krishnan E. Gout and the risk for incident heart failure and systolic dysfunction. BMJ Open. 2012;2(1):e000282. doi: 10.1136/bmjopen-2011-000282
  62. Richette P, Latourte A, Bardin T. Cardiac and renal protective effects of urate - lowering therapy. Rheumatology (Oxford). 2018;57(suppl 1):i47-i50. doi: 10.1093/rheumatology/kex432
  63. Kuo C.F, Grainge M.J, Mallen C, Zhang W, Doherty M. Impact of gout on the risk of atrial fibrillation. Rheumatology (Oxford). 2016;55(4):721-8. doi: 10.1093/rheumatology/kev418
  64. Chang K, Yokose C, Tenner C, Oh C, Donnino R, Choy-Shan A, Pike V.C, Shah B.D, Lorin J.D, Krasnokutsky S, et al. Association between gout and aortic stenosis. Am J Med. 2017;130(2):230.e1-8. doi: 10.1016/j.amjmed.2016.09.005
  65. Stack A.G, Hanley A, Casserly L.F, Cronin C.J, Abdalla A.A, Kiernan T.J, Murthy B.V, Hegarty A, Hannigan A, Nguyen H.T. Independent and conjoint associations of gout and hyperuricaemia with total and cardiovascular mortality. QJM. 2013;106(7):647-58. doi: 10.1093/qjmed/hct083
  66. Schumacher H.R. Jr, Becker M.A, Wortmann R.L, et al. Effects of febuxostat versus allopurinol and placebo in reducing serum urate in subjects with hyperuricemia and gout: a 28-week, phase III, randomized, double - blind, parallel - group trial. Arthritis Rheum. 2008;59:1540-8. doi: 10.1002/art.24209
  67. Becker M.A, Schumacher H.R. Jr, Wortmann R.L, et al. Febuxostat compared with allopurinol in patients with hyperuricemia and gout. N Engl J Med. 2005;353:2450-61. doi: 10.1056/NEJMoa050373
  68. Diaz-Torné C, Perez-Herrero N, Perez-Ruiz F. New medications in development for the treatment of hyperuricemia of gout. Curr Opin Rheumatol. 2015;27:164-9. doi: 10.1097/BOR.0000000000000146
  69. Edwards N.L, So A. Emerging therapies for gout. Rheum Dis Clin North Am. 2014;40:375-87. doi: 10.1016/j.rdc.2014.01.013
  70. Terkeltaub R.A, Furst D.E, Bennett K, et al. High versus low dosing of oral colchicine for early acute gout flare: twenty - four - hour outcome of the first multicenter, randomized, double - blind, placebo - controlled, parallel - group, dose - comparison colchicine study. Arthritis Rheum. 2010;62:1060-8. doi: 10.1002/art.27327
  71. Stamp L.K, O’Donnell J.L, Zhang M, et al. Using allopurinol above the dose based on creatinine clearance is effective and safe in patients with chronic gout, including those with renal impairment. Arthritis Rheum. 2011;63:412-21. doi: 10.1002/art.30119
  72. Stamp L.K, Taylor W.J, Jones P.B, et al. Starting dose is a risk factor for allopurinol hypersensitivity syndrome: a proposed safe starting dose of allopurinol. Arthritis Rheum. 2012;64:2529-36. doi: 10.1002/art.34488
  73. Hung S.I, Chung W.H, Liou L.B, et al. HLA-B*5801 allele as a genetic marker for severe cutaneous adverse reactions caused by allopurinol. Proc Natl Acad Sci USA. 2005;102:4134-9. doi: 10.1073/pnas.0409500102
  74. Akkineni R, Tapp S, Tosteson A.N.A, et al. Treatment of asymptomatic hyperuricemia and prevention of vascular disease: a decision analytic approach. J Rheumatol. 2014;41(4):739-48. doi: 10.3899/irheum.l21231
  75. Abeles A.M. Hyperuricemia, gout, and cardiovascular disease: an update. Curr Rheumatol Rep. 2015;17(3):13. doi: 10.1007//sll92601504952
  76. Lee J.E, Kim Y.G, Choi Y.H, et al. Serum uric acid is associated with microalbuminuria in prehypertension. Hypertension. 2006;47(5):962-7. doi: 10.1161/01.HYP.0000210550.97398x2
  77. Dalbeth N, Chen P, White M, et al. Impact of bariatric surgery on serum urate targets in people with morbid obesity and diabetes: a prospective longitudinal study. Ann Rheum Dis. 2014;73:797-802. doi: 10.1136/annrheumdis-2013-203970
  78. Chen J.H, Wen C.P, Wu S.B, et al. Attenuating the mortality risk of high serum uric acid: the role of physical activity underused. Ann Rheum Dis. 2015;74:2034-42. doi: 10.1136/annrheumdis-2014-205312
  79. Grimaldi-Bensouda L, Alperovitch A, Aubrun E, Danchin N, Rossignol M, Abenhaim L, Richette P. Impact of allopurinol on risk of myocardial infarction. Ann Rheum Dis. 2015;74(5):836-42. doi: 10.1136/annrheumdis-2012-202972
  80. De Abajo F.J, Gil M.J, Rodriguez A, Garcia-Poza P, Alvarez A, Bryant V, Garcia-Rodriguez L.A. Allopurinol use and risk of non - fatal acute myocardial infarction. Heart. 2015;101(9):679-85. doi: 10.1136/heartjnl-2014-306670
  81. Larsen K.S, Pottegard A, Lindegaard H.M, Hallas J. Effect of allopurinol on cardiovascular outcomes in hyperuricemic patients: a cohort study. Am J Med. 2016;129(3):299-306. doi: 10.1016/j.amjmed.2015.11.003
  82. Zhang J, Dierckx R, Mohee K, Clark A.L, Cleland J.G. Xanthine oxidase inhibition for the treatment of cardiovascular disease: an updated systematic review and meta - analysis. ESC Heart Fail. 2017;4(1):40-5. doi: 10.1002/ehf2.12112
  83. Kok V.C, Horng J.T, Chang W.S, Hong Y.F, Chang T.H. Allopurinol therapy in gout patients does not associate with beneficial cardiovascular outcomes: a population - based matched - cohort study. PLoS One. 2014;9(6):e99102. doi: 10.1371/journal.pone.0099102
  84. Borghi C, Tykarski A, Widecka K, et al. Expert consensus for diagnosis and treatment of patient with hyperuricemia and high cardiovascular risk. Cardiol J. 2018;25(5):545-64. doi: 10.5603/CJ.2018.0116
  85. Keenan R.T, O’Brien W.R, Lee K.H, et al. Prevalence of contraindications and prescription of pharmacologic therapies for gout. Am J Med. 2011;124:155-63. doi: 10.1016/j.amjmed.2010.09.012
  86. Nidorf S.M, Eikelboom J.W, Budgeon C.A, et al. Low - dose colchicine for secondary prevention of cardiovascular disease. J Am Coll Cardiol. 2013;61:404-10. doi: 10.1016/j.jacc.2012.10.027
  87. Deftereos S, Giannopoulos G, Raisakis K, et al. Colchicine treatment for the prevention of baremetal stent restenosis in diabetic patients. J Am Coll Cardiol. 2013;61:1679-85. doi: 10.1016/j.jacc.2013.01.055
  88. Rothenbacher D, Primatesta P, Ferreira A, et al. Frequency and risk factors of gout flares in a large population - based cohort of incident gout. Rheumatology (Oxford). 2011;50:973-81. doi: 10.1093/rheumatology/keq363
  89. Yamanaka H. Gout and hyperuricemia in young people. Curr Opin Rheumatol. 2011;23:156-60. doi: 10.1097/BOR.0b013e3283432d35
  90. Feig D.I, Soletsky B, Johnson R.J. Effect of allopurinol on blood pressure of adolescents with newly diagnosed essential hypertension: a randomized trial. JAMA. 2008;300(8):924-32. doi: 10.1001/jama.300.8.924
  91. Soletsky B, Feig D.I. Uric acid reduction rectifies prehypertension in obese adolescents. Hypertension. 2012;60(5):1148-56. doi: 10.1001/jama.300.8.924
  92. Mc Mullan C.J, Borgi L, Fisher N, Curhan G, Forman J. Effect of uric acid lowering on renin - angiotensin - system activation and ambulatory BP: a randomized controlled trial. Clin J Am Soc Nephrol. 2017;12(5):807-16. doi: 10.2215/CJN.10771016
  93. Poudel D.R, Karmacharya P, Donato A. Risk of acute gout among active smokers: data from nationwide inpatient sample. Clin Rheumatol. 2016;35(12):3015-8. doi: 10.1007/s10067-016-3415-6
  94. Gee Teng G, Pan A, Yuan J.M, Koh W.P. Cigarette smoking and the risk of incident gout in a prospective cohort study. Arthritis Care Res (Hoboken). 2016;68(8):1135-42. doi: 10.1002/acr.22821
  95. Wang W, Krishnan E. Cigarette smoking is associated with a reduction in the risk of incident gout: results from the Framingham Heart Study original cohort. Rheumatology (Oxford). 2015;54(1):91-5. doi: 10.1093/rheumatology/keu304
  96. Yu T.F, Gutman A.B. Study of the paradoxical effects of salicylate in low, intermediate and high dosage on the renal mechanisms for excretion of urate in man. J Clin Invest. 1959;38(8):1298-315. doi: 10.1172/JCI103905
  97. Zhang Y, Neogi T, Chen C, Chaisson C, Hunter D.J, Choi H. Low - dose aspirin use and recurrent gout attacks. Ann Rheum Dis. 2014;73(2):385-90. doi: 10.1136/annrheumdis-2012-202589
  98. Choi H.K, Soriano L.C, Zhang Y, Rodriguez L.A. Antihypertensive drugs and risk of incident gout among patients with hypertension: population based case - control study. BMJ. 2012;344:d8190. doi: 10.1136/bmj.d8190
  99. Stamp L.K, Barclay M.L, O’Donnell J.L, Zhang M, Drake J, Frampton C, Chapman P.T. Furosemide increases plasma oxypurinol without lowering serum urate - a complex drug interaction: implications for clinical practice. Rheumatology (Oxford). 2012;51(9):1670-6. doi: 10.1093/rheumatology/kes091
  100. Knake C, Stamp L, Bahn A. Molecular mechanism of an adverse drug - drug interaction of allopurinol and furosemide in gout treatment. Biochem Biophys Res Commun. 2014;452(1):157-62. doi: 10.1016/j. bbrc.2014.08.068
  101. Ramsay L.E, Shelton J.R, Harrison I.R. Plasma uric acid and spironolactone response in healthy subjects. Br J Clin Pharmacol. 1977;4(2):247-9.
  102. Takahashi S, Moriwaki Y, Yamamoto T, Tsutsumi Z, Ka T, Fukuchi M. Effects of combination treatment using anti - hyperuricaemic agents with fenofibrate and/or losartan on uric acid metabolism. Ann Rheum Dis. 2003;62(6):572-5.
  103. Mustard J.F, Murphy E.A, Ogryzlo M.A, Smythe H.A. Blood coagulation and platelet economy in subjects with primary gout. Can Med Assoc J. 1963;89:1207-11. PMID: 14084698
  104. Yang C.Y, Chen C.H, Deng S.T, Huang C.S, Lin Y.J, Chen Y.J, Wu C.Y, Hung S.I, Chung W.H. Allopurinol use and risk of fatal hypersensitivity reactions: a nationwide population - based study in Taiwan. JAMA Intern Med. 2015;175(9):1550-7. doi: 10.1001/jamainternmed.2015.3536
  105. Perez-Ruiz F, Martínez-Indart L, Carmona L, et al. Tophaceous gout and high level of hyperuricaemia are both associated with increased risk of mortality in patients with gout. Ann Rheum Dis. 2014;73(1):177-82. doi: 10.1136/annrheumdis-2012-202421
  106. Bhole V, Krishnan E. Gout and the heart. Rheum Dis Clin North Am. 2014;40:125-43.
  107. Agarwal V, Hans N, Messerli F.H. Effect of allopurinol on blood pressure: a systematic review and meta - analysis. J Clin Hypertens (Greenwich). 2013;15:435-42.
  108. Noman A, Ang D.S, Ogston S, et al. Effect of high - dose allopurinol on exercise in patients with chronic stable angina: a randomised, placebo controlled crossover trial. Lancet. 2010;375:2161-7. doi: 10.1016/SO140-6736(10)60391-1
  109. Kelkar A, Kuo A, Frishman WH. Allopurinol as a cardiovascular drug. Cardiol Rev. 2011;19:265-71.
  110. Thanassoulis G, Brophy J.M, Richard H, et al. Gout, allopurinol use, and heart failure outcomes. Arch Intern Med. 2010;170:1358-64. doi: 10.1136/bmjopen-2011-000282

Copyright (c) 2019 Consilium Medicum

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
 
 


This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies